نوع مقاله : مقاله پژوهشی

نویسندگان

1 گروه داخلی، دانشکده پزشکی، دانشگاه علوم پزشکی قم، قم، ایران

2 دستیار رادیولوژی، بخش رادیولوژی، دانشگاه علوم پزشکی رفسنجان، رفسنجان، ایران

3 واحد کمیته تحقیقات دانشجویی، دانشکده پزشکی، دانشگاه علوم پزشکی قم، قم، ایران

4 دکترای بخش معاونت تحقیقات و فناوری، دانشگاه علوم پزشکی قم، قم، ایران

5 واحدکمیته تحقیقات دانشجویی، دانشکده پزشکی، دانشگاه علوم پزشکی قم، قم، ایران

چکیده

زمینه و هدف  سندرم متابولیک، یک عامل خطر برای زوال عقل و درجات مختلف اختلال شناختی شناخته می‌شود. هدف از مطالعه حاضر، بررسی مقایسه‌ای ارزش تشخیصی آزمون شناختی مونترال وآزمون بررسی وضعیت ذهنی کوتاه شده در ارزیابی و غربالگری آسیب‌های شناختی بیماران مبتلا به سندرم متابولیک می‌باشد.
مواد و روش‌ها مطالعه حاضر، به روش توصیفی- تحلیلی بر روی 107 بیمار مبتلا به سندرم متابولیک انجام گرفت. آسیب شناختی توسط آزمون شناختی مونترال (MoCA) و آزمون بررسی وضعیت ذهنی کوتاه (MMSE) بررسی شد.
یافته‌ها میانگین نمره آزمون‌های MMSE و MoCa به ترتیب، 66/2±28/23 و 93/2±06/22 بود. 84 بیمار (%5/78) تست MoCA مختل (اختلال شناختی) داشتند. براساس تست MMSE، 66 بیمار (%68/61) مبتلا به اختلال شناختی بودند. حساسیت (Sensitivity) و ویژگی (Specificity) تست MMSE به ترتیب 81/73 درصد و 61/82 درصد بود.  تست تشخیصی MMSE با سن (000/0=p، 459/0- =CC (ضریب همبستگی))، BMI (000/0=p،338/0- CC=)، FBS  (000/0=p، 51/0-CC=)، سطح تری‌گلیسرید (TG) (000/0=p، 56/0- =CC) و HDL (000/0=p، 54/0-CC=) همبستگی معنادار داشت.
نتیجه‌گیری ابتلا به درجات مختلف اختلال شناختی در بیماران با سندرم متابولیک قابل توجه است و به نظر می‌رسد که مارکرهای سندرم متابولیک مانند قند خون ناشتا، سطح تری‌گلیسرید و HDL و LDL با اختلال شناختی در این بیماران مرتبط است. تست تشخیصی شناختی MMSE، ارزیابی اختلال شناختی در بیماران با سندرم متابولیک دارای حساسیت و اختصاصیت مطلوب است. با این حال، به علت کمبود مطالعات در این زمینه، انجام مطالعات بیشتر در آینده در راستای حصول نتیجه‌گیری جامع‌تر، توصیه می‌گردد.

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Comparative study of diagnostic value of Montreal cognitive assessment (MoCA) and Mini–Mental state examination (MMSE) tests for assessment and cognitive impairments screening in patients with metabolic syndrome

نویسندگان [English]

  • mahmoud parham 1
  • Sajad Rezvan 2
  • fatemeh amirkanian 3
  • akram barati 4
  • mohmmad hassan nikkhah 5

1 Department of Internal Medicine, Medical Faculty, Qom University of Medical Sciences, Qom, Iran

2 Radiology Assistant, Department of Radiology, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

3 Student Research Committee, Qom University of Medical Sciences, Qom, Iran

4 Deputy of research and technology, Qom University of Medical Sciences, Qom, Iran

5 Student Research Committee , Qom University of Medical Sciences, Qom, Iran

چکیده [English]

Introduction: Metabolic syndrome is known as a risk factor for dementia and various degrees of cognitive impairment. The aim of this study was to Comparative study of diagnostic value of Montreal cognitive assessment (MoCA) and Mini–Mental state examination (MMSE) tests for assessment and cognitive impairments screening in patients with metabolic syndrome.
Materials and Methods: This descriptive-analytical study was performed on 107 patients with metabolic syndrome. Cognitive impairment was examined by MoCA and MMSE tests.  Data were analyzed by SPSS 18 software.
Results: Mean score of MMSE and MoCa tests were 23.28 ± 2.66 and 22.06 ± 2.93, respectively. 84 patients (78.5%) had a MoCA test impairment (cognitive impairment). Based on the MMSE test, 66 patients (61.68%) had cognitive impairment. The sensitivity and specificity of the MMSE test were 73.81% and 82.61% respectively. MMSE diagnostic test with age (p=0.000, CC= -0.459), BMI (p = 0.000, CC = -0.338), FBS (p = 0.000, CC=-0.51), the levels of triglyceride (TG) (p = 0.000, CC = -0.56) and HDL (p = 0.000, CC = -0.54) were significantly correlated.
Conclusion: Cognitive impairment is noticeable in patients with metabolic syndrome and it seems that metabolic syndrome markers such as fasting blood glucose, triglyceride levelsand ets associated with cognitive impairment in these patients. MMSE test is a desirable sensitivity and specificity in evaluating cognitive impairment in patients with metabolic syndrome. However, because of the lack of studies in this field, are recommended for more comprehensive conclusions.

کلیدواژه‌ها [English]

  • Metabolic syndrome
  • Cognitive impairment
  • MoCA،MMSE
[1]. Seow LS, Chong SA, Wang P, Shafie S, Ong HL, Subramaniam M. Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care. Compr Psychiatry. 2017 Apr;74:196-203. [2]. Kelishadi R, Hovsepian S, Djalalinia S, Jamshidi F, Qorbani M. A systematic review on the prevalence of metabolic syndrome in Iranian children and adolescents. J Res Med Sci. 2016;21:90.
[3]. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162
[4]. Mardani, Mahnaz and Rafiee, Ezatolah and Ebrahimzadeh, Farzad and Baba, Hoshang and Balavar, Saeed and Alimohamadi, Maryam ,Prevalence of metabolic syndrome among students of Lorestan University of Medical Sciences during 2011-1012. medical journal of mashhad university of medical sciences, (2015) 57 (8). pp. 918-925. ( Farsi)
[5]. Montazerifar F, Bolouri A, Mahmoudi Mozaffar M, Karajibani M. The Prevalence of Metabolic Syndrome in  Coronary Artery Disease Patients Cardiol Res. 2016 Dec;7(6):202-208 (Farsi)
[6]. Carol E. Greenwood, Gordon Winocur. High-fat diets, insulin resistance and declining cognitive function Neurobiology of Aging: 26S (2005) 42–45.
[7]. Tsai CK1, Kao TW, Lee JT, Wu CJ, Hueng DY, Liang CS, Wang GC, Yang FC, Chen WL. Increased risk of cognitive impairment in patients with components of metabolic syndrome. 2016 Sep;95(36).
[8]. Frisardi V. Impact of metabolic syndrome on cognitive decline in older age: protective or harmful, where is the pitfall? J Alzheimers Dis. 2014;41(1):163-7.
[9]. Panza F1, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. 2010;21:691-724.
[10]. Bora E1, Akdede BB2, Alptekin K2. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. 2017 Apr;47:1030-1040.
[11]. Ojeda N, Del Pino R, Ibarretxe-Bilbao N, Schretlen DJ, Pena J. [Montreal Cognitive Assessment Test: normalization and standardization for Spanish population]. 2016 Dec 1;63(11):488-496.
[12]. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The  Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.
[13]. Kessler, J., Markowitsch, H. J. & Denzler, P. Mini-Mental-Status-Test (MMST). Göttingen: Beltz Test GMBH. [Deutsche Adaption] (2000).
[14]. Bokura H, Nagai A, Oguro H, Kobayashi S, Yamaguchi S. The association of metabolic syndrome with executive dysfunction independent of subclinicalischemic brain lesions in Japanese adults. Dement Geriatr Cogn Disord. 2010;30:479-85.
[15]. Gatto NM, Henderson VW, St John JA, McCleary C, Hodis HN, Mack WJ. Metabolic syndrome and cognitivefunction in healthy middleaged and older adults without diabetes. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2008 Sep;15:627-41.
[16]. Andreana P. Haley,Mitzi M. GonzalesTakashi Tarumi,Steven C. Miles,Katayoon Goudarzi,Hirofumi Tanaka, Elevated cerebral glutamate and myo-inositol levels in cognitively normal middle-aged adults with metabolic syndrome, December 2010, Volume 25, Issue 4, pp 397–405
[17]. Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Helkala EL, Haapala I, et al. Metabolic syndrome and cognitive function: a population-based follow-up study in elderly women. Dement Geriatr Cogn Disord. 2007;23:29-34
[18]. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement Geriatr Cogn Disord. 2007;24(3):185-92.
[19]. Bora E, Akdede BB, Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017 Apr;47(6):1030-1040.
[20]. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.
[21]. Emsaki G, Molavi H, Chitsaz A, Movahed AM, Asgari K. Psychometric Properties of the Montreal Cognitive Assessment (MoCA) in Parkinson's Disease Patients in Isfahan. J Isfahan Med Sci. 2011; 29(158):1-10.
[22]. Sanchez N. A life course perspective on polycystic ovary syndrome. Int J Womens Health. 2014;6:115–122.
[23]. Almedia, O. P. Mini-Mental State Examination and the diagnosis of dementia in Brazil. Archives of Neuropsychiatrist. 1998; 56, 605-612.
[24]. Maziar Sayyidan. Preparation and validation of the Persian version of the short test of mental status. Scientific Journal of the Islamic Republic of Iran Medical Organization.2009؛25:408-414.(In Persian).
[25]. Frisardi V. Impact of metabolic syndrome on cognitive decline in older age: protective or harmful, where is the pitfall? J Alzheimers Dis. 2014;41(1):163-7.
[26]. Paraizo Mde A, Almeida AL, Pires LA, Abrita RS, Crivellari MH, Pereira Bdos S, Fernandes NM, Bastos MG. Montreal Cognitive Assessment (MoCA) screening mild cognitive impairment in patients with chronic kidney disease (CKD) pre-dialysis. J Bras Nefrol. 2016 Mar;38(1):31-41.
[27]. Sikaroodi, H., Yadegari, S., Miri, S.R. Cognitive impairments in patients with cerebrovascular risk factors: A comparison of Mini Mental Status Exam and Montreal Cognitive Assessment Clinical Neurology and Neurosurgery, Volume 115, Issue 8, August 2013.
[28]. Tiffin-Richards, Frances E., et al. The Montreal Cognitive Assessment (MoCA)-A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. PloS one. 2014; 9.10
[29]. Dong Y, Sharma VK, Chan BP, Venketasubramanian N, Teoh HL, Seet RC, Tanicala S, Chan YH, Chen C. The Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination (MMSE) for the detection of vascular cognitive impairment after acute stroke. J Neurol Sci. 2010 Dec 15;299(1-2):15-8.